Esperion Therapeutics, Inc.ESPRNASDAQ

Revenue (LTM)

$403M

+21.3% YoY

Net Income (LTM)

$-23M

+56.2% YoY

Free Cash Flow

$-13M

Revenue CAGR (5Y)

+12.1%

Marginsdeclining

FCF($0.0B)

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	78	75↓3.8%	116↑54.1%	332↑185.7%	403↑21.3%
Gross Profit	64	49↓24.5%	73↑50.6%	264↑260.9%	274↑3.9%
Operating Income	-227	-180↑20.8%	-156↑13.3%	54↑135.0%	60↑10.8%
Net Income	-269	-234↑13.2%	-209↑10.4%	-52↑75.3%	-23↑56.2%
EBITDA	-222	-176↑20.6%	-150↑14.9%	8↑105.0%	60↑696.3%
EPS Diluted	-11.03	-4.33↑60.7%	-2.03↑53.1%	-0.28↑86.2%	-0.11↑60.7%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	209	125↓40.3%	82↓34.1%	145↑76.0%	168↑16.0%
Total Current Assets	329	247↓25.0%	201↓18.5%	338↑68.1%	168↓50.3%
Total Assets	382	248↓35.0%	206↓17.0%	344↑67.1%	466↑35.5%
Total Current Liabilities	73	92↑25.8%	156↑69.2%	246↑57.6%	301↑22.2%
Total Liabilities	579	572↓1.2%	661↑15.6%	733↑10.9%	768↑4.8%
Total Equity	-197	-324↓64.4%	-455↓40.5%	-389↑14.6%	-302↑22.3%
Total Debt	260	261↑0.3%	541↑107.3%	591↑9.3%	548↓7.3%
Net Debt	51	136↑165.4%	459↑236.9%	446↓2.7%	380↓14.9%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-264	-175↑33.7%	-135↑22.5%	-24↑82.5%	-13↑44.6%
Capital Expenditure	0	0	0	-0	0↑159.6%
Free Cash Flow	-264	-175↑33.7%	-135↑22.5%	-24↑82.3%	-13↑46.2%
Stock-Based Comp	24	15↓37.4%	12↓21.4%	12↑0.3%	10↓17.7%
Net Change in Cash	-46	-134↓191.1%	-43↑68.3%	63↑247.0%	23↓63.1%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance